Cargando…
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study
OBJECTIVES: Our study aims at comparing the efficacy and safety of IFN-based therapy (lopinavir/ritonavir, ribavirin, and interferon β-1b) vs. favipiravir (FPV) in a cohort of hospitalized patients with non-critical COVID-19. METHODS: Single center observational study comparing IFN-based therapy (in...
Autores principales: | A. Malhani, Areej, A. Enani, Mushira, Saheb Sharif-Askari, Fatemeh, R. Alghareeb, Mona, T. Bin-Brikan, Roaa, A. AlShahrani, Safar, Halwani, Rabih, Tleyjeh, Imad M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191942/ https://www.ncbi.nlm.nih.gov/pubmed/34111191 http://dx.doi.org/10.1371/journal.pone.0252984 |
Ejemplares similares
-
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021) -
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
por: Al-Muhsen, Saleh, et al.
Publicado: (2022) -
Ciclesonide/favipiravir/lopinavir/ritonavir: Off-label use, pancytopenia and liver dysfunction: case report
Publicado: (2021) -
Lopinavir/ritonavir/ribavirin: Various toxicities following off-label treatment: case report
Publicado: (2020) -
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)